PMA Consultants — Professional Advisory Services

PMA consultants help medical device manufacturers prepare and manage FDA Premarket Approval activities for Class III devices. Their work can include regulatory strategy, submission readiness assessments, technical documentation review, clinical evidence planning, risk management alignment, mock meeting preparation, deficiency response support, and change impact assessments. The goal is to reduce avoidable delays, strengthen submission quality, and improve regulatory defensibility throughout the approval process.

A PMA is generally required for Class III medical devices that support or sustain human life, are implanted, or present potentially significant risk. Unlike a 510(k), which relies on substantial equivalence to a predicate, PMA requires valid scientific evidence demonstrating safety and effectiveness. A consultant can help confirm classification, review product claims, and determine whether PMA, De Novo, or another pathway is appropriate before major submission work begins.

PMA consulting reduces delays by identifying documentation gaps, evidence weaknesses, traceability issues, and quality system misalignment before FDA review begins. Consultants assess whether technical files, clinical support, labeling, and risk management records are truly submission-ready. They also help structure the dossier clearly and prepare for likely reviewer questions. This proactive work can prevent deficiency cycles, repeated revisions, and timeline slippage caused by incomplete or inconsistent submissions.

A PMA readiness assessment typically reviews device documentation, clinical evidence, risk management files, quality system alignment, labeling, and the consistency of claims across the submission package. It is designed to benchmark your materials against the actual regulatory expectations FDA will apply during review. The output is usually a prioritized gap analysis with remediation recommendations, helping your team understand what must be fixed before filing.

Yes. Elexes provides support for regulatory agency action responses, including FDA inquiries, deficiency letters, and follow-up requests. This includes analyzing each issue, coordinating technical inputs, organizing supporting evidence, and drafting clear, defensible responses. The objective is to address reviewer concerns directly, reduce the chance of repeated questions, and keep the PMA review process moving as efficiently as possible.

Yes. PMA success depends on more than the submission itself, so consultants often review quality system alignment, internal audit readiness, design history records, and risk management documentation. Elexes supports ISO 13485, ISO 14971, MDSAP, and related compliance activities that strengthen the credibility of the submission package. This integrated approach helps ensure the evidence behind the PMA is complete, traceable, and audit-defensible.

PMA advisory services are especially valuable for manufacturers developing Class III devices, startups building their first FDA submission strategy, scaling companies with limited in-house RAQA bandwidth, and established firms managing complex changes or remediation work. They are also useful for teams re-engaging FDA after a hold or deficiency cycle. External expertise helps organizations make faster, better-informed decisions without expanding permanent headcount.

Yes. PMA consultants can help evaluate whether design, software, manufacturing, labeling, or process changes require supplements, amendments, or other FDA action. They may also support complaint handling, post-market surveillance governance, audit readiness, and ongoing RAQA operations. This is important because compliance obligations continue after approval, and poorly assessed changes can create regulatory exposure even for already marketed devices.